Radiotherapy is a key treatment for various cancers often in combination with other therapies.<\/p>\n
In this study, we investigated whether radiotherapy enhances the effectiveness of DNA damage response (DDR) agents in the A549 and MDA-MB-436 preclinical xenograft models. Specifically, inhibitors targeting DNA-dependent protein kinase (DNA-PK) or poly-(ADP-ribose)-polymerase (PARP) were used either as monotherapy or in combination with radiotherapy.<\/p>\n
The evaluation of monotherapy and combination treatment regimens revealed that A549 and MDA-MB-436 xenograft models exhibit increased sensitivity to DDR agents when exposed to radiotherapy both in vitro<\/em> and in vivo<\/em>.<\/p>\n More specifically:<\/p>\n These findings demonstrate that radiotherapy can sensitise preclinical xenograft models to DNA damage response (DDR) agents both in vitro<\/em> and in vivo<\/em>. The data highlight the utility and value of the radiotherapy platform for testing the efficacy of novel therapeutic agents in combination with a clinically relevant standard of care in drug discovery research.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":2856,"template":"","category":[740,685,738],"class_list":["post-4126","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-ex-vivo-tissue-analysis","category-in-vivo-pharmacology","category-oncology-models"],"acf":[],"yoast_head":"\n\n